Utah's Nolla Health AI acne prescription pilot

Before Nolla's AI can write anything, it processes two inputs: a facial scan and a patient questionnaire that takes 10-15 minutes to complete. From those, it produces a numerical acne severity score and picks from a fixed menu of pre-approved topical medications - it has no authority to improvise a regimen of its own ^[1]. Dr. Zaid Fadul, Nolla's Chief Medical Advisor, frames the constraint as the whole point: "The AI can't improvise. It can only choose from a short list of physician-approved topical treatments" ^[2]. Isotretinoin, a stronger oral acne drug with serious side-effect risks, and every other oral medication are hard excluded, and any case that looks severe, involves pregnancy, or falls outside the pilot's narrow scope gets routed to a licensed physician or in-person care instead ^[3]. The safety net that actually matters is temporal: every one of the first 100 prescriptions needs sign-off from two independent physicians before it reaches a patient, and only once that cohort clears does oversight loosen into after-the-fact review ^[1]. All of this runs behind a $4.99-a-month subscription open to Utah residents 18 and older ^[4].

Acne was not chosen at random. It is high-volume, rarely life-threatening, and has a narrow, well-defined set of first-line topical treatments - exactly the profile regulators would pick for a first experiment in letting software make an initial prescribing decision. Nolla says its severity-scoring model was trained on more than 100,000 labeled acne cases and hit an R-squared of 0.947 on a held-out test set of over 10,000 cases, with licensed clinicians agreeing with the AI's recommendation in more than 96% of real-world cases so far ^[5]. The company is already looking past acne: Dr. Fadul has floated expanding AI-issued prescriptions to flu and uncomplicated UTIs, while explicitly ruling out controlled substances such as opioids and benzodiazepines ^[2]. That roadmap is the real story here - acne is the low-risk beachhead for a model of care the company clearly intends to generalize.

Nolla's pilot did not appear out of nowhere. Utah's Office of Artificial Intelligence Policy first tested AI-driven prescribing in January 2026 with Doctronic, which was allowed to autonomously renew, not initiate, prescriptions across 191 chronic-condition medications ^[9]. That narrower refill pilot drew real pushback: by July 2026, CNN reported physicians were wary of the program's safety and oversight model even as Utah prepared to go further ^[8]. Doctronic's agreement established the regulatory and operational template, safety checks, state reporting, data privacy terms, that Utah's Office of Artificial Intelligence Policy and Division of Professional Licensing then extended to Nolla's far more consequential initial-prescription authority ^[7]. Separately, Utah's broader healthcare AI sandbox pillar now contracts six outside evaluators, including the Coalition for Health AI and Stanford's Clinical Excellence Research Center, to stress-test guardrails and inspect decision logs across pilots like Nolla's ^[10]. Utah's own Office of AI Policy director, Zach Boyd, frames the whole structure around one constraint: "Our foundational approach is that technical innovation will never supersede patient safety" ^[10]. The state is also explicit that none of this amounts to an endorsement - the sandbox agreement states that participation does not mean the state approves, endorses, or certifies the product ^[6], leaving the liability question for an AI-caused error conspicuously unresolved as oversight intensity declines over the program's three phases.

Because Nolla's AI diagnoses from a facial photograph, it inherits a well-documented weak spot in image-based dermatology models: training sets that skew toward lighter skin tones tend to produce worse performance on darker skin ^[11]. Nolla has not published a demographic breakdown of its training data or error rates across skin types ^[11], even as the company separately touts a roughly 96% clinician-agreement rate on its treatment recommendations overall ^[5]. That gap matters more here than in a typical AI-bias story, because the output isn't a recommendation a human doctor filters - during the program's most autonomous phase, it's a prescription that ships to the patient's door with no human check on that specific image at all.

The loudest reaction came from Nolla's own CEO, Luis Wenus, who called the approval a milestone for the first "end-to-end AI doctor" in the US. The response inside medicine itself was more split. On r/medicalschool, the dominant thread wasn't really about acne - it was about whether this is the opening move in automating "bread and butter" cognitive medicine, with the role of the physician shifting as a result. A separate strand of skepticism argued the move is dystopian, noting that acne can occasionally mask an underlying hormonal or systemic condition that a face scan alone would never catch, and that "increased access" framing can obscure that this is also a subscription-revenue product. Dr. Fadul's own video is unusually candid about the stakes of getting this wrong, noting that a bad first-time diagnosis is more consequential than a bad refill because it can send a patient down the wrong treatment path for months. And a recurring, half-serious critique ties the whole debate together: if an AI with no medical license can safely pick the right cream without a doctor in the loop, why not just skip the prescription requirement and sell the treatment over the counter?